Characteristics and Outcomes for Hispanic/Latinx Participants With Statin Intolerance Receiving Bempedoic Acid

J Am Coll Cardiol. 2024 May 28;83(21):2130-2132. doi: 10.1016/j.jacc.2024.03.390. Epub 2024 Mar 25.

Authors

Fatima Rodriguez¹, Leslie Cho², JoAnne Foody³, A Michael Lincoff², Lei Lei³, Stephen J Nicholls⁴, Steven E Nissen², Heather A Powell³, Jorge Plutzky⁵

Affiliations

¹ Cardiovascular Institute, and the Center for Digital Health, Stanford University School of Medicine, Stanford, California, USA. Electronic address: frodrigu@stanford.edu.
² Cleveland Clinic, Cleveland, Ohio, USA.
³ Esperion Therapeutics, Inc, Ann Arbor, Michigan, USA.
⁴ Victorian Heart Institute, Monash University, Victoria, Australia.
⁵ Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

PMID: 38537915
DOI: 10.1016/j.jacc.2024.03.390

No abstract available

Publication types

Letter

MeSH terms

Aged
Dicarboxylic Acids* / therapeutic use
Fatty Acids*
Female
Hispanic or Latino*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / administration & dosage
Hypolipidemic Agents* / adverse effects
Hypolipidemic Agents* / therapeutic use
Latin America
Male
Middle Aged
North America
Treatment Outcome

Substances

8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
Dicarboxylic Acids
Fatty Acids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents

Grants and funding

K01 HL144607/HL/NHLBI NIH HHS/United States